GSE139540 menadione 3 v 2 human up (Gene Set)

Analyze

Playbook Workflow Builder
Playbook Workflow Builder: Gene Set Enrichment

Perform Gene Set Enrichment with this gene set against Common Fund program's gene sets, identifying significant overlaps using a pre-built PWB workflow. Run the workflow with GSE139540_menadione_3_v_2_human_up.

GeneSetCart
GeneSetCart

GeneSetCart helps you to fetch gene sets from various data sources, augment, combine with set operations, visualize and analyze these gene sets in a single session. Start a new session with GSE139540_menadione_3_v_2_human_up.

CFDE-GSE
CFDE Gene Set Enrichment (GSE)

CFDE-GSE illuminates connections between the input gene set and various CF gene sets that overlap with the queried gene set. Query CFDE-GSE with GSE139540_menadione_3_v_2_human_up.

Playbook Workflow Builder
Playbook Workflow Builder

The Playbook Workflow Builder helps you interactively construct workflows leveraging CFDE APIs without code. Start a new workflow with GSE139540_menadione_3_v_2_human_up.

Results found

Linked to

 

Label

Description

 

Gene

Pvt1 oncogene

Gene

urothelial cancer associated 1

Gene

long intergenic non-protein coding RNA, p53 induced transcript

Gene

C10orf95 antisense RNA 1

Gene

family with sequence similarity 86 member D, pseudogene

Gene

long intergenic non-protein coding RNA 1410

Gene

C-type lectin domain family 4 member O, pseudogene

Gene

PRDM8 antisense RNA 1

Gene

TMEM132D antisense RNA 1

Gene

ubiquitin B pseudogene 4


  • Gene

    urothelial cancer associated 1


  • Gene

    long intergenic non-protein coding RNA, p53 induced transcript


  • Gene

    C10orf95 antisense RNA 1


  • Gene

    family with sequence similarity 86 member D, pseudogene


  • Gene

    long intergenic non-protein coding RNA 1410


  • Gene

    C-type lectin domain family 4 member O, pseudogene


  • Gene

    PRDM8 antisense RNA 1


  • Gene

    TMEM132D antisense RNA 1


  • Gene

    ubiquitin B pseudogene 4

  • DISPLAY PER PAGE
    This repository is under review for potential modification in compliance with Administration directives.